Eli Lilly and Company (LLY) Market Cap, Stock Prices, Chart & Financials

Eli Lilly and Company
LLY
$323.0

PriceChangeChange %MarketcapOpenHighLowCloseVolume52 Week RangeEPSDividend RateDividend YieldSectorIndustryEmployeesCountryLast Updated
$323.0$5.41.70%306.9B$318.2$324.7$317.7$317.62,489,187
6.733.531.111391HealthcareDrug Manufacturers—General34,914United States9 hours ago

Eli Lilly Market Cap (2001 – 2022)

YearMarket cap
2022$306,901,680,128.0
2021$264.22 B
2020$161.50 B
2019$125.84 B
2018$122.38 B
2017$92.99 B
2016$81.19 B
2015$93.12 B
2014$76.62 B
2013$56.95 B
2012$56.54 B
2011$48.11 B
2010$40.37 B
2009$41.03 B
2008$45.78 B
2007$60.56 B
2006$58.95 B
2005$63.95 B
2004$64.23 B
2003$79.03 B
2002$71.27 B
2001$88.22 B

Eli Lilly Annual Revenue & Earnings (2001 – 2021)

YearRevenueEarnings
2021$27.75 B$7.13 B
2020$24.53 B$7.58 B
2019$22.31 B$5.66 B
2018$24.55 B$4.06 B
2017$22.87 B$2.42 B
2016$21.22 B$3.55 B
2015$19.95 B$2.95 B
2014$19.61 B$3.14 B
2013$23.11 B$6.04 B
2012$22.60 B$5.58 B
2011$24.28 B$5.53 B
2010$23.07 B$6.71 B
2009$21.83 B$5.61 B
2008$20.37 B$5.52 B
2007$18.63 B$4.80 B
2006$15.69 B$4.12 B
2005$14.64 B$3.64 B
2004$13.85 B$3.65 B
2003$12.58 B$3.50 B
2002$11.07 B$3.32 B
2001$11.54 B$3.72 B

About Eli Lilly and Company

Eli Lilly and Company
Sector: Healthcare
Industry: Drug Manufacturers—General
Exchange: NYQ
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; MiNA Therapeutics Limited; Verge Genomics; and The Banner Alzheimer's Institute, as well as Kumquat Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

0 Comments

Your email address will not be published.